- GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drugJideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer as…BioSpace · 1d ago↗ source
- Lilly's triple agonist heads to regulators after two more Phase 3 obesity winsRetatrutide, the obesity candidate that has shown the most powerful weight loss in late-stage trials, will be filed for approval early next year, its developer Eli Lilly said Thursday. The filing…Endpoints · 1d ago↗ source
- Roche says it is thoughtful on token use for AI, shelves a drug from Carmot buyRoche has offered some insight into how it is using AI, from drug discovery to token use. AI has already contributed to “a significant increase in new molecules” in its pipeline, CEO Thomas Schin…